Correspondence 0001193125-25-014239 from Maze Therapeutics, Inc. (MAZE) (CIK 0001842295) (MAZE)
Maze Therapeutics, Inc. (MAZE) (CIK 0001842295)
Date: Jan. 28, 2025 · CIK: 0001842295 · Accession: 0001193125-25-014239
AI Filing Summary & Sentiment
File numbers found in text: 001-42490, 333-284164
Letter
Maze Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco, California 94080
January 28, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC
Attention:
Jimmy McNamara
Suzanne Hayes
Sasha Parikh
Kevin Vaughn
Re:
Maze Therapeutics, Inc.
Registration Statement on Form S-1, as amended (File No. 333-284164) and
corresponding Registration Statement on Form 8-A (File No. 001-42490)
Request for Acceleration of Effective Date
Requested Date: January 30, 2025
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Maze Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Amanda Rose, Ryan Mitteness or Chelsea Anderson, each of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553, or in her absence, Mr. Mitteness at (206) 389-4533 or Ms. Anderson at (206) 389-4516.
Sincerely,
MAZE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Maze Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco, California 94080 January 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jimmy McNamara Suzanne Hayes Sasha Parikh Kevin Vaughn Re: Maze Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-284164) and corresponding Registration Statement on Form 8-A (File No. 001-42490) Request for Acceleration of Effective Date Requested Date: January 30, 2025 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Maze Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Registrant hereby authorizes Amanda Rose, Ryan Mitteness or Chelsea Anderson, each of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553, or in her absence, Mr. Mitteness at (206) 389-4533 or Ms. Anderson at (206) 389-4516. Sincerely, MAZE THERAPEUTICS, INC. By: /s/ Courtney Phillips Courtney Phillips General Counsel and Corporate Secretary cc: Jason Coloma, Ph.D., Chief Executive Officer Maze Therapeutics, Inc. Effie Toshav, Esq. Amanda Rose, Esq. Ryan Mitteness, Esq. Chelsea Anderson, Esq. Fenwick & West LLP Alan F. Denenberg, Esq. Emily Roberts, Esq. Elsie Cheang, Esq. Davis Polk & Wardwell LLP